Comparative Pharmacology
Head-to-head clinical analysis: JADENU versus JADENU SPRINKLE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: JADENU versus JADENU SPRINKLE.
JADENU vs JADENU SPRINKLE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Deferasirox is an oral iron chelator that binds trivalent iron (Fe3+) with high affinity, forming a stable complex that is excreted primarily in the feces.
Deferasirox is an oral iron chelator that selectively binds iron (Fe3+) with high affinity, forming a stable complex that is excreted primarily in the feces. It reduces iron overload by promoting iron excretion.
30 mg/kg once daily orally, up to a maximum of 60 mg/kg/day, for iron chelation in patients with thalassemia or other chronic iron overload; dose should be adjusted based on serum ferritin levels and therapeutic response.
Oral: Initial 20 mg/kg/day (max 30 mg/kg/day) administered once daily; titrate based on serum ferritin. For patients >14 years with serum ferritin >1000 mcg/L, use 20 mg/kg/day. Sprinkle capsules can be opened and contents sprinkled on soft food.
None Documented
None Documented
Terminal elimination half-life is 8-16 hours (mean ~12 h) in patients with transfusional iron overload, allowing once-daily dosing.
8–28 hours (mean 11–19 hours); prolonged half-life correlates with iron overload and may require dose adjustments.
Primarily fecal (hepatobiliary) ~75-90% as unchanged drug and iron complex; renal excretion of deferasirox is minimal (<5% unchanged).
Primarily fecal (84% of absorbed dose); renal excretion accounts for approximately 8% of total clearance.
Category C
Category C
Iron Chelator
Iron Chelator